Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13,287 Mln
Revenue (TTM)
$502 Mln
Net Profit (TTM)
$0 Mln
ROE
-17.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
123.7
Industry P/E
--
EV/EBITDA
-9.4
Div. Yield
0 %
Debt to Equity
-1.3
Book Value
$--
EPS
$-3.8
Face value
--
Shares outstanding
193,862,871
CFO
$-2,275.58 Mln
EBITDA
$-2,443.03 Mln
Net Profit
$-2,682.14 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BridgeBio Pharma (BBIO)
| -10.4 | 0.9 | -10.3 | 97.1 | 71.5 | 0.8 | -- |
|
BSE Sensex
| -12.5 | -11.1 | -13.4 | -3.7 | 8.5 | 8.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
BridgeBio Pharma (BBIO)
| 178.8 | -31.8 | 429.8 | -54.3 | -76.5 | 102.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BridgeBio Pharma (BBIO)
|
68.5 | 13,287.4 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 |
| 11.3 | 3,410.4 | 510.2 | 146.9 | 37.2 | 35.6 | 23.9 | 7.2 | |
| 12.1 | 3,722.1 | 3,018.8 | 72.1 | 12.6 | -80 | 53.8 | 86.1 | |
| 158.8 | 8,027.0 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.0 | |
| 33.8 | 3,684.8 | 761.4 | 99.7 | 7.3 | 15 | 42.2 | 5.7 | |
| 24.9 | 11,922.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.9 | |
| 7.6 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 201.7 | 4,084.1 | 268.1 | 124.5 | 60.0 | 13.5 | 33.5 | 4.0 | |
| 35.2 | 3,208.3 | 158.3 | -68.9 | -29.3 | -113 | -- | 71.7 | |
| 62.0 | 2,932.6 | 1,103.8 | 186.5 | 27.9 | 10.1 | 15.8 | 1.6 |
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of... cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California. Read more
Co-Founder, President, CEO & Director
Dr. Neil Kumar Ph.D.
Co-Founder, President, CEO & Director
Dr. Neil Kumar Ph.D.
Headquarters
Palo Alto, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of BridgeBio Pharma Inc (BBIO) is $68.53 (NASDAQ) as of 24-Mar-2026 16:00 EDT. BridgeBio Pharma Inc (BBIO) has given a return of 71.52% in the last 3 years.
Since, TTM earnings of BridgeBio Pharma Inc (BBIO) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-20.14
|
-7.07
|
|
2024
|
-9.53
|
-3.48
|
|
2023
|
-10.23
|
-4.86
|
|
2022
|
-2.33
|
-0.89
|
|
2021
|
-4.27
|
-2.76
|
The 52-week high and low of BridgeBio Pharma Inc (BBIO) are Rs 84.94 and Rs 28.33 as of 25-Mar-2026.
BridgeBio Pharma Inc (BBIO) has a market capitalisation of $ 13,287 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in BridgeBio Pharma Inc (BBIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.07
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.